Lately, it has been discovered that CDK4/6 inhibition elevate PD-L1 expression by restraining its degradation mediated by cyclin D-CDK4 and the SPOP ligase, and the combination of CDK4/6 inhibitors and anti-PD-1 therapy enhances tumor regression and dramatically improves overall survival of murine tumor models (Zhang J. et al., 2017). The gene discussed is CDK4; the disease is neoplasm.